Submit Manuscript  

Article Details

Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer

[ Vol. 19 , Issue. 6 ]


C. Barinka, C. Rojas, B. Slusher and M. Pomper   Pages 856 - 870 ( 15 )


Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc metallopeptidase with the highest expression levels found in the nervous and prostatic tissue. Throughout the nervous system, glia-bound GCPII is intimately involved in the neuronneuron and neuron-glia signaling via the hydrolysis of N-acetylaspartylglutamate (NAAG), the most abundant mammalian peptidic neurotransmitter. The inhibition of the GCPII-controlled NAAG catabolism has been shown to attenuate neurotoxicity associated with enhanced glutamate transmission and GCPII-specific inhibitors demonstrate efficacy in multiple preclinical models including traumatic brain injury, stroke, neuropathic and inflammatory pain, amyotrophic lateral sclerosis, and schizophrenia. The second major area of pharmacological interventions targeting GCPII focuses on prostate carcinoma; GCPII expression levels are highly increased in androgenindependent and metastatic disease. Consequently, the enzyme serves as a potential target for imaging and therapy. This review offers a summary of GCPII structure, physiological functions in healthy tissues, and its association with various pathologies. The review also outlines the development of GCPII-specific small-molecule compounds and their use in preclinical and clinical settings.


Metalloprotease, prostate-specific membrane antigen, glutamate excitotoxicity, prostate cancer, N-acetylaspartylglutamate, Glutamate carboxypeptidase, hydrolysis, neurotoxicity, metastatic disease, pathologies


Institute of Biotechnology AS CR, v.v.i.,Laboratory of Structural Biology, Videnska 1083, 14200 Praha 4, Czech Republic.

Read Full-Text article